Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

A Randomised, Double-blind, Six-period, Cross-over, Dose-response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects of Blacks or African American, Whites of Hispanic or Latino Origin and Whites Not of Hispanic or Latino Origin With Type 2 Diabetes

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.

Inclusion Criteria:

• Type 2 diabetes
• Insulin treatment with any insulin preparation/regimen for at least three months with or without combination with below or equal to 2 oral antidiabetic agents (OADs)
• Duration of diabetes at least 12 months
• Body Mass Index (BMI) below 33 kg/m^2
• HbA1c maximum 10 % based on analysis from the central laboratory

Exclusion Criteria:

• Current treatment with insulin above 1.2 U/kg/day
• Current treatment with drugs known to interfere with glucose metabolism other than OADs such as systemic corticosteroids, non-selective beta-blockers, and monoamino oxidase (MAO) inhibitors
• Blood donation of more than 500 mL within the last three months